Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
AR Kansal, Y Zheng, T Pokora, SV Sorensen - Best Practice & Research …, 2013 - Elsevier
Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …
high human and economic burden. Novel oral anticoagulants have been approved in many …
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
J Mendoza-Sanchez, F Silva, L Rangel, L Jaramillo… - PLoS …, 2018 - journals.plos.org
Introduction Warfarin and new oral anticoagulants are effective in reducing stroke in atrial
fibrillation; however, the benefits and risks rates in clinical trials show heterogeneity for each …
fibrillation; however, the benefits and risks rates in clinical trials show heterogeneity for each …
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation
WJ Canestaro, AR Patrick, J Avorn, K Ito… - … Quality and Outcomes, 2013 - Am Heart Assoc
Background—New anticoagulants may improve health outcomes in patients with atrial
fibrillation, but it is unclear whether their use is cost-effective. Methods and Results—A …
fibrillation, but it is unclear whether their use is cost-effective. Methods and Results—A …
[HTML][HTML] Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries
M Krejczy, J Harenberg, S Marx, K Obermann… - Blood, 2012 - Elsevier
Abstract 1164 The three new oral anticoagulants (NOAC) dabigatran 110mg bid and 150mg
bid, investigated in the RE-LY trial, rivaroxaban 20mg od of the ROCKET trial, and apixaban …
bid, investigated in the RE-LY trial, rivaroxaban 20mg od of the ROCKET trial, and apixaban …
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients≥ 75 and< …
S Deitelzweig, A Amin, Y Jing… - Journal of Medical …, 2013 - Taylor & Francis
Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature
Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …
The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model
M Sussman, M Di Fusco, CY Tao, JD Guo… - Journal of Medical …, 2021 - Taylor & Francis
Background Despite treatment guidelines recommending the use of oral anticoagulants
(OACs) for patients with non-valvular atrial fibrillation (NVAF) and moderate to high risk of …
(OACs) for patients with non-valvular atrial fibrillation (NVAF) and moderate to high risk of …
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the …
JB Briere, O Wu, K Bowrin, A Millier… - Current Medical …, 2019 - Taylor & Francis
Objective: The aim of this study was to investigate the impact of methodological choices in a
meta-analysis of real-world evidence (RWE) comparing three non-vitamin-K antagonist oral …
meta-analysis of real-world evidence (RWE) comparing three non-vitamin-K antagonist oral …
Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA
S Deitelzweig, AD Dhamane, M Di Fusco… - Journal of Medical …, 2020 - Taylor & Francis
Objective To evaluate utilization of anticoagulants (ACs) and the predictors of treatment of
patients with a diagnosis of atrial fibrillation (AF) during a hospital stay in the USA. Methods …
patients with a diagnosis of atrial fibrillation (AF) during a hospital stay in the USA. Methods …
Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants
HM Rozjabek, CI Coleman, V Ashton… - Journal of Medical …, 2019 - Taylor & Francis
Objective: To assess long-term healthcare costs related to ischemic stroke and systemic
embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial …
embolism (stroke/SE) and major bleeding (MB) events in patients with non-valvular atrial …